Sign in
TerminatedNo phase

Evaluation of the Microbiome in Multiple Sclerosis

Key facts

Who runs it
Nimble Science Ltd.
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
40 people enrolled
Started
26 Jun 2023
Ended
24 Apr 2024
Type of study
Interventional
Treatments tested
  • SIMBA Capsule
Record updated
15 May 2025
Why it stopped
Financial constraints and study recruitment phase exceeded the time allotted

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age between 18 and 60 years inclusive
  • Have diagnosis of Multiple Sclerosis (relapsing remitting or secondary progressive for the MS cohort) or be a healthy individual living in the same household (non-MS for the healthy control cohort)
  • No antibiotics, or colon cleanses/bowel preparation in the previous 2 weeks
  • Written informed consent

Who cannot take part

  • Known disease which, in the investigator's opinion, would lead to intestinal stricture or obstruction with a risk of capsule non-excretion (particular diseases which would be assessed on a case-by-case basis would include, achalasia, eosinophilic esophagitis, diverticulitis, Crohn's disease, Ulcerative colitis, cancer diagnosis or treatment within the past year, or previous oesophageal, gastric, small intestinal, or colonic surgery. 3) Appendectomy or cholecystectomy more than 3 months prior to enrolment are acceptable). The main deciding factor would be history of obstructive symptoms in the previous 3 months prior to entry
  • Use of any medications in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics, laxatives), or acidity (PPI, H2RA); for both groups
  • Known to have swallowing disorders
  • < 2 bowel movements per week (for both groups)
  • Risk or suspect of being pregnant

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To access the small intestinal microbiome and find abnormal microbiome/metabolome signature in luminal fluid samples from small bowel in MS compared to HC that could be used as biomarkers for MS.

The group in the trial

  • Single ArmTreatment being tested

    Participant swallows and retrieves capsule in stool. Intestinal fluid samples collected by SIMBA capsules from the MS and HC participants, along with a fecal and blood samples, will be used for gut microbiome, viral and metabolomic analysis.

    Treatment: SIMBA Capsule

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Clinical Study To Evaluate Small Intestine Microbiome In Multiple Sclerosis (MS)
Record updated
15 May 2025